April 5, 2001

 

 

Dear Members, Consultants, Speakers and Guests:

Thank you for your willingness to participate in the Pediatric Advisory Subcommittee meeting on Tuesday, April 24, 2001.

The focus of the meeting will be the clinical development of antimuscarinics for drooling in children with cerebral palsy and other neurologic disorders. Discussion will include how to assess adverse effects in this patient population, defining the optimal dosing regimen and the ethics of studying this vulnerable pediatric patient population.

The speakers will provide the background for the questions to be discussed. The articles included in this package maybe helpful in your preparation for the meeting.

Looking forward to seeing you on April 24, 2001.

 

Sincerely,

 

 

 

Rosemary Roberts, M.D.

Team Leader, Pediatric Team

CDER, FDA

 

 

 

Attachments